Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland
about
The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in AfricaCurrent global status & impact of human papillomavirus vaccination: Implications for IndiaHuman papillomavirus and head and neck carcinomas: focus on evidence in the babel of published dataAdverse event monitoring of the human papillomavirus vaccines in Scotland.Epidemiological investigation of the relationship between common lower genital tract infections and high-risk human papillomavirus infections among women in Beijing, China.Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types.Human papillomavirus vaccination: the population impact.Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis.Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012.Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies.Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population.HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girlsEffect of human papillomavirus vaccination on cervical cancer screening in Alberta.Declines in HPV-associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, US, 2008-2015.An update on barriers to adolescent human papillomavirus vaccination in the USA.Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology.The changing landscape of cervical screening-What does the future hold for primary care?Overview of the benefits and potential issues of the nonavalent HPV vaccine.Primary HPV testing: a proposal for co-testing in initial rounds of screening to optimise sensitivity of cervical cancer screening.Human papillomavirus vaccination crisis in Japan.The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study.Novel Approaches for Vaccination Against HPV-Induced Cancers.Tumour virus vaccines: hepatitis B virus and human papillomavirus.Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.Reply to Ryser et al.Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.Impact of HPV vaccination with Gardasil® in Switzerland.Monitoring the impact of HPV vaccine in males-Considerations and challenges.Declaration to demand the resumption of recommendations for human papillomavirus (HPV) vaccination for cervical cancer prevention.Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia.HPV prophylactic vaccines: lessons learned from 10 years experienceCervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine IntroductionImmune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
P2860
Q26799584-D7FD9B82-3235-4BD2-82FC-4E79D2F00FA9Q28079776-125FDF03-343F-416A-B67C-AC65F7984A15Q31136389-6ECD1A95-54ED-4C99-9D82-004DD61F2544Q33429171-9EBFCB8E-E751-4EBF-B552-747D401AB583Q33713068-A7B9927F-6AE5-4F7D-83B9-D41B1C33A76BQ33774640-8AFFD1F3-6B18-4890-A37C-6A8EE28287B7Q33806566-5DCC46DF-158A-4AEA-8B6C-24A8F0BAA7C5Q33810515-095C66EC-F573-4E11-AE86-9E45F2FABEF3Q35997434-309DDAFC-B8B8-47E7-9EDF-7468844A6678Q36269739-C2F24001-B928-4F48-8B90-DFD53DED78D7Q36418117-38E5C22B-5EB2-4557-B98B-5CA8D4D663AFQ36486778-D4EE1743-65C1-45CD-A432-E0A99E1AAA0BQ36662008-E5D3CDD0-571A-45FE-8608-4CD386576C56Q36964366-E5EFFA65-06D3-4CE9-8223-C474167345FDQ37135272-7EE1218F-E06C-4C1E-812E-964BC2AB9100Q37135276-78AEC386-25CF-4267-B01A-385386085ACBQ37227066-0C68E891-BBD2-4B9C-9FE8-C87A4A734EAFQ37834158-7F005702-0727-41D4-B3E5-D5D56382B59BQ38570369-75F9BDF0-3E83-4066-B3A6-EDF18BFC4D0BQ38673879-F135270C-FDF7-4510-86ED-3CD813036188Q38691747-946E2EB5-7742-44F3-8620-F4CD3FA8FBD0Q38770473-66E223A5-4E51-410F-BBD8-D7E7763ADF5FQ38785689-4B4B94B5-EABE-4B0B-B167-57890AB83996Q38935708-3AE59312-0BB4-45F6-A9DE-B7420822F413Q39012582-EDB0242B-46A5-4E56-A0ED-11A925602BBDQ39012586-A6D64187-D503-4F22-BF2A-CD7FD559DA31Q39033362-6867ACDC-8CBA-42D4-8E54-E477BE22ED34Q40046649-98E9C739-3E03-4A58-89CC-E93165B93FE4Q40805660-B19D9ADA-CAD2-4631-9D6B-F733C0FDD0B3Q41655617-D7F9A4F1-E443-47DE-A5A7-BABD6F358B95Q44701708-1707A9D1-67C8-4306-99B0-7B7FEE155E53Q44841725-62130D07-F2C6-4F42-9E37-4B35755DF30CQ47257772-0C14157E-D24E-4833-BC8A-0D74047A1653Q50091385-382D7C4C-FE4D-45A1-9944-E668B8565595Q54152226-8488B25C-8E97-4F46-A21B-8FF1CBD24629Q55262571-8ACE5AD5-3538-48C5-8F44-B0C27FB7EA90Q56067928-4E84EFB6-DA19-416C-A710-AC786ED63F5FQ56772407-9533E1C1-AD4E-4E31-B151-9BF379A358EBQ57932049-5715505B-CA8B-42E9-887D-B449DFBBAF5E
P2860
Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Reduction of low- and high-gra ...... V bivalent vaccine in Scotland
@ast
Reduction of low- and high-gra ...... V bivalent vaccine in Scotland
@en
type
label
Reduction of low- and high-gra ...... V bivalent vaccine in Scotland
@ast
Reduction of low- and high-gra ...... V bivalent vaccine in Scotland
@en
prefLabel
Reduction of low- and high-gra ...... V bivalent vaccine in Scotland
@ast
Reduction of low- and high-gra ...... V bivalent vaccine in Scotland
@en
P2093
P2860
P356
P1476
Reduction of low- and high-gra ...... V bivalent vaccine in Scotland
@en
P2093
C Robertson
K Cuschieri
K G J Pollock
M Cruickshank
T J Palmer
P2860
P2888
P304
P356
10.1038/BJC.2014.479
P407
P577
2014-09-02T00:00:00Z